1829. Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared to Healthy Subjects
Session: Poster Abstract Session: Clinical Study with New Antibiotics and Antifungals
Saturday, October 7, 2017
Room: Poster Hall CD
Background:

Eravacycline (ERV) is a fluorocycline being developed for the treatment of serious infections, including those caused by multidrug-resistant pathogens. The PK of ERV in subjects with end stage renal disease (ESRD) or hepatic impairment (HI) were investigated.

Methods:

Two multi-center studies were completed; one in subjects with ESRD and one in subjects with mild, moderate or severe HI based upon Child-Pugh scoring. Each included a cohort of healthy subjects (HS) matched by gender, age and BMI. A single IV dose of 1.5 mg/kg ERV was administered. PK parameters were calculated using standard non-compartmental methods and within study comparisons of PK for the ESRD and HI subjects were made with HS.

Results:

The following comparative AUCinf and Cmax values for ERV were observed:

Subjects Status (n)

Ratio of Geometric LS Mean (%)

90% CI for Ratio (%)

Intra-subject CV (%)

ESRD

AUC0‑inf (ng*hr/mL/kg)

ESRD (6) vs. HS (6)

96

(82, 112)

15

Cmax (ng/mL)

ESRD (6) vs. HS (6)

109

(82, 145)

28

HI

AUC0‑inf (ng*hr/mL/kg)

Mild (4) vs. HS (5)

123

(84, 180)

34

Moderate (5) vs. HS (5)

138

(96, 198)

34

Severe (6) vs. HS (5)

210

(149, 297)

34

Cmax (ng/mL)

Mild (6) vs. HS (6)

114

(89, 145)

25

Moderate (6) vs. HS (6)

116

(91, 148)

25

Severe (6) vs. HS (6)

120

(94, 153)

25

For all groups, except severe HI, the 90% CI for the ratio of AUCinf and Cmax compared to HS contains 100%, indicating similar exposures. For subjects with severe HI, Cmax was similar to that in HS while AUCinf was about 2-fold higher.

ERV was well tolerated with 2 or fewer subjects in any group reporting drug-related adverse events (1 subject with severe HI).

Conclusion:

Following a single IV dose of ERV, the systemic exposures in subjects with ESRD and mild or moderate hepatic impairment were similar to those observed in HS. The 2-fold increase in AUCinf observed in subjects with severe HI did not result in increased adverse events. Therefore, no dose adjustment should be required when ERV is given to subjects with either renal or hepatic impairment.

Funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No HHSO100201200002C.

Patrick Horn, MD, PhD1, Susan Redican, MS2 and Melanie Olesky, PhD1, (1)Tetraphase Pharmaceuticals, Watertown, MA, (2)Clinical Operations, Tetraphase Pharmaceuticals, Watertown, MA

Disclosures:

P. Horn, Tetraphase Pharmaceuticals: Employee , Salary

S. Redican, Tetraphase Pharmaceuticals: Employee , Salary

M. Olesky, Tetraphase Pharmaceuticals: Employee , Salary

Previous Abstract | Next Abstract >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.